We analysed a collection of 95 multiply antibiotic-resistant pneumococci, recovered since 1988 from 14 Spanish hospitals, that have MICs > or = 0.25 microgram benzylpenicillin ml-1. The majority of the isolates were of serogroups 14, 23, 6, 19 and 15, which are currently the serogroups mainly associated with multiresistance in Spain. All of the serogroup 23 isolates were members of the major Spanish serotype 23F multiresistant clone. Similarly, most of the serogroup 6 isolates were members of the major multiresistant serotype 6B clone, or variants of this clone. Eighteen of the 24 isolates of serogroup 19 were members of a highly penicillin-resistant clone that appears to be a serotype 19F variant of the major Spanish serotype 23F multiresistant clone. Eighteen of the 25 isolates of serotype 14 were members of a previously uncharacterized highly penicillin-resistant clone. Thirteen of the 16 isolates of serogroup 15 were members of a single previously unreported clone of serotype 15F that had moderate levels of resistance to penicillin. Approximately 65% of the multiresistant pneumococci that are currently circulating in Spain were members of the three new clones of serotype 14, 15F and 19F that we describe here, or the previously described serotype 6B and 23F clones. The other 35% of isolates were minor variants of the major clones, unrelated minor clones, and unique isolates, many of which appeared to have arisen by horizontal gene transfer events.

Download full-text PDF

Source
http://dx.doi.org/10.1099/13500872-142-10-2747DOI Listing

Publication Analysis

Top Keywords

serotype 23f
12
multiply antibiotic-resistant
8
spanish hospitals
8
major clones
8
isolates
8
serogroup isolates
8
isolates members
8
members major
8
major spanish
8
serotype
8

Similar Publications

Background: The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for standalone or sequential use in the elderly in many countries to prevent pneumococcal disease, making it crucial to assess vaccine response and long-term persistence.

Purpose: We aimed to describe the trajectories of circulating antibody levels to the PPSV23 in the elderly following immunization.

Methods: Eligible individuals aged 65 to 70 years were enrolled and vaccinated with one dose of PPSV23.

View Article and Find Full Text PDF

Objectives: This study aimed to evaluate the immunogenicity and safety of a 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/TT) (PCV13i) in infants.

Methods: A total of 1200 infants were randomly assigned to either the experimental PCV13i group or the control PCV13 group in a 1:1 ratio. Each group received a three-dose series of the vaccine at 2, 4, and 6 months of age, followed by a booster dose at 12-15 months.

View Article and Find Full Text PDF

Background: is a transmitted respiratory pathogen that causes high morbidity and mortality in children, especially those under 5 years of age. During the implementation of population control measures for COVID-19 in mainland China, the detection rate in pediatric patients decreased. However, with the second wave of the COVID-19 pandemic (2022), the incidence of pneumococcal disease (PD) and even invasive pneumococcal disease (IPD) began to rise again.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined pneumococcal disease in internally displaced people (IDP) in Somaliland, revealing a 36% overall carriage rate, with 70% in children under 5.
  • Researchers found that 41% of strains carried were from the 10-valent PNEUMOSIL vaccine, potentially causing over half of the invasive diseases.
  • The results indicate that implementing pneumococcal conjugate vaccines (PCV) could significantly reduce the disease burden in this vulnerable population.
View Article and Find Full Text PDF

Background & objectives The Pneumococcal vaccines were introduced under the Universal Immunization Programme (UIP) in 2021 in India. Drawing from the collective experience of various nations, it is anticipated that there will be a substantial shift in serotype patterns following the introduction of this vaccine. The available data is limited to years until 2018 when the vaccine was introduced in only five States.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!